These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 17911471)
1. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. Fuchs S; Feferman T; Zhu KY; Meidler R; Margalit R; Wang N; Laub O; Souroujon MC Ann N Y Acad Sci; 2007 Sep; 1110():550-8. PubMed ID: 17911471 [TBL] [Abstract][Full Text] [Related]
2. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Brenner T; Laub O; Souroujon MC Ann N Y Acad Sci; 2008; 1132():244-8. PubMed ID: 18567875 [TBL] [Abstract][Full Text] [Related]
3. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. Fuchs S; Feferman T; Meidler R; Margalit R; Sicsic C; Wang N; Zhu KY; Brenner T; Laub O; Souroujon MC J Neuroimmunol; 2008 Feb; 194(1-2):89-96. PubMed ID: 18178258 [TBL] [Abstract][Full Text] [Related]
4. The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model. Fuchs S; Feferman T; Meidler R; Brenner T; Laub O; Souroujon MC Isr Med Assoc J; 2008 Jan; 10(1):58-60. PubMed ID: 18300576 [TBL] [Abstract][Full Text] [Related]
12. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455 [TBL] [Abstract][Full Text] [Related]
13. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines. Li XL; Liu Y; Cao LL; Li H; Yue LT; Wang S; Zhang M; Li XH; Dou YC; Duan RS Mol Cell Neurosci; 2013 Sep; 56():85-95. PubMed ID: 23541702 [TBL] [Abstract][Full Text] [Related]
14. Development of novel therapies for MG: Studies in animal models. Souroujon MC; Brenner T; Fuchs S Autoimmunity; 2010 Aug; 43(5-6):446-60. PubMed ID: 20298126 [TBL] [Abstract][Full Text] [Related]
15. Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis. Souroujon MC; Aricha R; Feferman T; Mizrachi K; Reuveni D; Fuchs S Ann N Y Acad Sci; 2012 Dec; 1274():120-6. PubMed ID: 23252906 [TBL] [Abstract][Full Text] [Related]
16. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Kong QF; Sun B; Wang GY; Zhai DX; Mu LL; Wang DD; Wang JH; Li R; Li HL Eur J Immunol; 2009 Mar; 39(3):800-9. PubMed ID: 19283707 [TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. MacMillan HF; Lee T; Issekutz AC Clin Immunol; 2009 Aug; 132(2):222-33. PubMed ID: 19447680 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)]. Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459 [TBL] [Abstract][Full Text] [Related]